These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 7908790

  • 1. [Microtubules and antineoplastic drugs].
    Arioka H, Saijo N.
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):583-90. PubMed ID: 7908790
    [Abstract] [Full Text] [Related]

  • 2. [Antimitotic agents].
    Fukuoka K, Saijo N.
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1519-25. PubMed ID: 9309150
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
    Dumontet C, Sikic BI.
    J Clin Oncol; 1999 Mar; 17(3):1061-70. PubMed ID: 10071301
    [Abstract] [Full Text] [Related]

  • 4. [Properties of antitumor activity of vinorelbine tartrate, a new vinca alkaloid antitumor agent].
    Kanazawa J, Morimoto M, Ohmori K.
    Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):215-23. PubMed ID: 11084918
    [Abstract] [Full Text] [Related]

  • 5. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
    Jordan A, Hadfield JA, Lawrence NJ, McGown AT.
    Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
    [Abstract] [Full Text] [Related]

  • 6. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC, Chen X, Parissenti AM, Joy AA, Tuszynski J, Brindley DN, Wang Z.
    PLoS One; 2017 Jul; 12(8):e0182400. PubMed ID: 28787019
    [Abstract] [Full Text] [Related]

  • 7. [Antimicrotubule agents].
    Niitani H, Hisakatsu S.
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):34-41. PubMed ID: 8093658
    [Abstract] [Full Text] [Related]

  • 8. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
    Jordan MA.
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
    [Abstract] [Full Text] [Related]

  • 9. Anticancer therapy with novel tubulin-interacting drugs.
    Kavallaris M, Verrills NM, Hill BT.
    Drug Resist Updat; 2001 Dec; 4(6):392-401. PubMed ID: 12030786
    [Abstract] [Full Text] [Related]

  • 10. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes.
    van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G.
    Oncol Rep; 1998 Dec; 5(1):249-55. PubMed ID: 9458331
    [Abstract] [Full Text] [Related]

  • 11. Taxol (paclitaxel): mechanisms of action.
    Horwitz SB.
    Ann Oncol; 1994 Dec; 5 Suppl 6():S3-6. PubMed ID: 7865431
    [Abstract] [Full Text] [Related]

  • 12. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
    Kruczynski A, Hill BT.
    Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
    [Abstract] [Full Text] [Related]

  • 13. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
    Aparicio LM, Pulido EG, Gallego GA.
    Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
    [Abstract] [Full Text] [Related]

  • 14. Microtubule active agents: beyond the taxane frontier.
    Morris PG, Fornier MN.
    Clin Cancer Res; 2008 Nov 15; 14(22):7167-72. PubMed ID: 19010832
    [Abstract] [Full Text] [Related]

  • 15. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA, Ducki S, Hirst N, McGown AT.
    Prog Cell Cycle Res; 2003 Nov 15; 5():309-25. PubMed ID: 14593726
    [Abstract] [Full Text] [Related]

  • 16. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD, Kumar D, Krishna KV, Kantevari S.
    Curr Top Med Chem; 2017 Nov 15; 17(22):2523-2537. PubMed ID: 28056738
    [Abstract] [Full Text] [Related]

  • 17. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol).
    Long BH, Carboni JM, Wasserman AJ, Cornell LA, Casazza AM, Jensen PR, Lindel T, Fenical W, Fairchild CR.
    Cancer Res; 1998 Mar 15; 58(6):1111-5. PubMed ID: 9515790
    [Abstract] [Full Text] [Related]

  • 18. [Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes].
    Chazard M, Pellae-Cosset B, Garet F, Soares JA, Lucidi B, Lavail Y, Lenaz L.
    Bull Cancer; 1994 Mar 15; 81(3):173-81. PubMed ID: 7894125
    [Abstract] [Full Text] [Related]

  • 19. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol.
    ter Haar E, Kowalski RJ, Hamel E, Lin CM, Longley RE, Gunasekera SP, Rosenkranz HS, Day BW.
    Biochemistry; 1996 Jan 09; 35(1):243-50. PubMed ID: 8555181
    [Abstract] [Full Text] [Related]

  • 20. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
    Zhang Y, Yang SH, Guo XL.
    Biomed Pharmacother; 2017 Dec 09; 96():659-666. PubMed ID: 29035832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.